178 related articles for article (PubMed ID: 28098927)
1. The role of HE4 and CA125 in differentiation between malignant and non-malignant endometrial pathologies.
Abdalla N; Pazura M; Słomka A; Piórkowski R; Sawicki W; Cendrowski K
Ginekol Pol; 2016; 87(12):781-786. PubMed ID: 28098927
[TBL] [Abstract][Full Text] [Related]
2. CA125 and HE4 levels in a Czech female population diagnosed with endometrial cancer in preoperative management.
Presl J; Novotny Z; Topolcan O; Vlasak P; Kucera R; Fuchsova R; Vrzalova J; Betincova L; Svobodova S
Anticancer Res; 2014 Jan; 34(1):327-31. PubMed ID: 24403483
[TBL] [Abstract][Full Text] [Related]
3. HE4 is superior to CA125 in the detection of recurrent disease in high-risk endometrial cancer patients.
Abbink K; Zusterzeel PL; Geurts-Moespot AJ; Herwaarden AEV; Pijnenborg JM; Sweep FC; Massuger LF
Tumour Biol; 2018 Feb; 40(2):1010428318757103. PubMed ID: 29463191
[TBL] [Abstract][Full Text] [Related]
4. HE4 and CA125 as preoperative risk stratifiers for lymph node metastasis in endometrioid carcinoma of the endometrium: A retrospective study in a cohort with histological proof of lymph node status.
O'Toole SA; Huang Y; Norris L; Power Foley M; Shireen R; McDonald S; Kamran W; Ibrahim N; Ward M; Thompson C; Murphy C; D'Arcy T; Farah N; Heron E; O'Leary JJ; Abu Saadeh F; Gleeson N
Gynecol Oncol; 2021 Feb; 160(2):514-519. PubMed ID: 33213897
[TBL] [Abstract][Full Text] [Related]
5. Serum HE4 superior to CA125 in predicting poorer surgical outcome of epithelial ovarian cancer.
Shen Y; Li L
Tumour Biol; 2016 Nov; 37(11):14765-14772. PubMed ID: 27629144
[TBL] [Abstract][Full Text] [Related]
6. Clinical Significance of Serum HE4, CA125, CA724, and CA19-9 in Patients With Endometrial Cancer.
Bian J; Sun X; Li B; Ming L
Technol Cancer Res Treat; 2017 Aug; 16(4):435-439. PubMed ID: 27562869
[TBL] [Abstract][Full Text] [Related]
7. Serum human epididymis protein 4 vs. carbohydrate antigen 125 and their combination for endometrial cancer diagnosis: a meta-analysis.
Chen Y; Ren YL; Li N; Yi XF; Wang HY
Eur Rev Med Pharmacol Sci; 2016 May; 20(10):1974-85. PubMed ID: 27249595
[TBL] [Abstract][Full Text] [Related]
8. Utility of HE4 to identify patients with endometrioid endometrial cancer who may require lymphadenectomy.
Dobrzycka B; Mackowiak-Matejczyk B; Terlikowska KM; Kinalski M; Terlikowski SJ
Adv Med Sci; 2016 Mar; 61(1):23-7. PubMed ID: 26344910
[TBL] [Abstract][Full Text] [Related]
9. Predictive value of serum HE4 and CA125 concentrations for lymphatic metastasis of endometrial cancer.
Wang Y; Han C; Teng F; Bai Z; Tian W; Xue F
Int J Gynaecol Obstet; 2017 Jan; 136(1):58-63. PubMed ID: 28099710
[TBL] [Abstract][Full Text] [Related]
10. Importance of Preoperative Knowledge of the Biomarker HE4 in Early-stage Endometrial Cancer Regarding Surgical Management.
Presl J; Ovesna P; Novotny Z; Vlasak P; Bouda J; Kostun J; Topolcan O; Kucera R; Bednarikova M; Weinberger V
Anticancer Res; 2017 May; 37(5):2697-2702. PubMed ID: 28476847
[TBL] [Abstract][Full Text] [Related]
11. HE4 and CA125 levels in the preoperative assessment of endometrial cancer patients: a prospective multicenter study (ENDOMET).
Antonsen SL; Høgdall E; Christensen IJ; Lydolph M; Tabor A; Loft Jakobsen A; Fagö-Olsen CL; Andersen ES; Jochumsen K; Høgdall C
Acta Obstet Gynecol Scand; 2013 Nov; 92(11):1313-22. PubMed ID: 24032654
[TBL] [Abstract][Full Text] [Related]
12. The role of novel biomarker HE4 in endometrial cancer: a case control prospective study.
Angioli R; Plotti F; Capriglione S; Montera R; Damiani P; Ricciardi R; Aloisi A; Luvero D; Cafà EV; Dugo N; Angelucci M; Benedetti-Panici P
Tumour Biol; 2013 Feb; 34(1):571-6. PubMed ID: 23179397
[TBL] [Abstract][Full Text] [Related]
13. Prognostic value of human epididymis protein 4 in endometrial cancer and its utility for surgical staging.
Minar L; Klabenesova I; Jandakova E; Zlamal F; Bienertova-Vasku J
J Obstet Gynaecol Res; 2015 Oct; 41(10):1644-52. PubMed ID: 26223178
[TBL] [Abstract][Full Text] [Related]
14. Serum HE4 detects recurrent endometrial cancer in patients undergoing routine clinical surveillance.
Brennan DJ; Hackethal A; Mann KP; Mutz-Dehbalaie I; Fiegl H; Marth C; Obermair A
BMC Cancer; 2015 Feb; 15():33. PubMed ID: 25655024
[TBL] [Abstract][Full Text] [Related]
15. Development of a multimarker assay for differential diagnosis of benign and malignant pelvic masses.
Chen X; Zhou H; Chen R; He J; Wang Y; Huang L; Sun L; Duan C; Luo X; Yan H
Clin Chim Acta; 2015 Feb; 440():57-63. PubMed ID: 25447698
[TBL] [Abstract][Full Text] [Related]
16. Association of Serum HE4 with Primary Tumor Diameter and Depth of Myometrial Invasion in Endometrial Cancer Patients at Rajavithi Hospital.
Prueksaritanond N; Cheanpracha P; Yanaranop M
Asian Pac J Cancer Prev; 2016; 17(3):1489-92. PubMed ID: 27039795
[TBL] [Abstract][Full Text] [Related]
17. Serum HE4 as a prognostic marker in endometrial cancer--a population based study.
Brennan DJ; Hackethal A; Metcalf AM; Coward J; Ferguson K; Oehler MK; Quinn MA; Janda M; Leung Y; Freemantle M; ; Webb PM; Spurdle AB; Obermair A
Gynecol Oncol; 2014 Jan; 132(1):159-65. PubMed ID: 24211402
[TBL] [Abstract][Full Text] [Related]
18. The role of HE4 in differentiating benign and malignant endometrial pathology.
Gąsiorowska E; Magnowska M; Iżycka N; Warchoł W; Nowak-Markwitz E
Ginekol Pol; 2016; 87(4):260-4. PubMed ID: 27321096
[TBL] [Abstract][Full Text] [Related]
19. HE4 and mesothelin: novel biomarkers of ovarian carcinoma in patients with pelvic masses.
Abdel-Azeez HA; Labib HA; Sharaf SM; Refai AN
Asian Pac J Cancer Prev; 2010; 11(1):111-6. PubMed ID: 20593939
[TBL] [Abstract][Full Text] [Related]
20. Utility of a novel serum tumor biomarker HE4 in patients with endometrioid adenocarcinoma of the uterus.
Moore RG; Brown AK; Miller MC; Badgwell D; Lu Z; Allard WJ; Granai CO; Bast RC; Lu K
Gynecol Oncol; 2008 Aug; 110(2):196-201. PubMed ID: 18495222
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]